Another NZ Public Healthcare Provider Signs Up to Cxbladder

Company Announcement
14 August 2018
1

ANOTHER NEW ZEALAND PUBLIC HEALTHCARE PROVIDER SIGNS UP TO CXBLADDER
Counties Manukau Health to Adopt Cxbladder Tests for Application Across the Clinical Pathway

Cancer diagnostics company Pacific Edge (NZX: PEB) has received notification from Counties Manukau District
Health Board (CMDHB) regarding adoption of the suite of Cxbladder cancer diagnostic tests for use across
the clinical pathway.

From September, Cxbladder will be incorporated into the standard of care by CMDHB across the bladder
cancer pathway from investigation of haematuria (blood in the urine) and initial diagnosis, through to post-
treatment surveillance.

Counties Manukau is New Zealand’s second largest DHB and serves an estimated population of over half a
million people, representing approximately 12% of New Zealand’s population.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “This is a big step forward for Cxbladder in
New Zealand and for the urology patients in the Auckland region. We are aware of lengthy waiting times for
patients referred to CMDHB for investigation of haematuria and based on our experience with Cxbladder in
other DHBs, and the growing body of peer-reviewed clinical publications, we are confident that Cxbladder
will have a significant impact on the timeliness and quality of care for these urology patients.”

The agreement with Counties Manukau follows successful commercial implementation by a number of New
Zealand DHBs. Canterbury, Waitemata, MidCentral and BOP/Lakes DHBs have incorporated Cxbladder into
their clinical pathways for urology services and are now routinely using the tests. This reflects the growing
recognition of Cxbladder by large healthcare organisations, both in New Zealand and internationally.

Pacific Edge CEO David Darling, said: “The addition of Counties Manuakau DHB to the list of New Zealand’s
public healthcare providers who have adopted Cxbladder commercially, provides further evidence of the
broad clinical buy-in from New Zealand’s urologists who are now routinely using Cxbladder. The New Zealand
public healthcare system is leading the way with the adoption and integration of Cxbladder into their
standard of care where more than 50% of the population now have ready access to Cxbladder through their
local DHB.”

ENDS

For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

Company Announcement
14 August 2018
2
OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company
is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international
multi-centre clinical studies.

Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results,
and better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through
the company’s dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA.
Cxbladder Resolve launched in New Zealand in December 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who
have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand,
Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder
Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective
adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular
diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient
specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate
of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of
urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of
patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers
measured from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who
are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary
evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist
clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for
whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation
in high throughput settings.

Refer to www.cxbladder.com for more information.